title: Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
abstract: Sunitinib is an orally administered inhibitor of tyrosine kinases and has become the standard of care for many patients with metastatic renal cell carcinoma. Its use has been associated with renal toxicity in some patients. We report a patient with a metastatic clear-cell renal carcinoma who showed arterial hypertension, nephrotic syndrome and azotaemia 10 months after treatment with sunitinib. The renal biopsy revealed focal segmental glomerulosclerosis (FSGS) in addition to thrombotic microangiopathy (TMA), and the complete syndrome disappeared 6 months after sunitinib withdrawal. To our knowledge, this is the first case of FSGS associated to TMA secondary to sunitinib treatment. We discuss the possible glomerular pathomechanism.
authors.affiliation: Department of Nephrology, La Paz University Hospital, Madrid, Spain. olgacostero@hotmail.com
authors.forename: Olga
authors.initials: O
authors.lastname: Costero
authors.forename: Mari Luz
authors.initials: ML
authors.lastname: Picazo
authors.forename: Pilar
authors.initials: P
authors.lastname: Zamora
authors.forename: Sara
authors.initials: S
authors.lastname: Romero
authors.forename: Jorge
authors.initials: J
authors.lastname: Martinez-Ara
authors.forename: Rafael
authors.initials: R
authors.lastname: Selgas
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D004656:Enalapril / Q000627:therapeutic use; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D057049:Thrombotic Microangiopathies / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D004656:Enalapril; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib